Uncovering Mitochondrial Determinants of Racial Disparities in Ovarian Cancer

Bandera, 2016, Racial/ethnic disparities in ovarian cancer treatment and survival, Clin. Cancer Res., 22, 5909, 10.1158/1078-0432.CCR-16-1119 Choudhury, 2017, Mitochondrial determinants of cancer health disparities, Semin. Cancer Biol., 47, 125, 10.1016/j.semcancer.2017.05.001 Romero, 2012, Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity, Obstet. Gynecol., 119, 61, 10.1097/AOG.0b013e3182393ab3 Li, 2019, Signaling pathway network alterations in human ovarian cancers identified with quantitative mitochondrial proteomics, EPMA J., 10, 153, 10.1007/s13167-019-00170-5 Xie, 2019, MicroRNA-663 facilitates the growth, migration and invasion of ovarian cancer cell by inhibiting TUSC2, Biol. Res., 52, 18, 10.1186/s40659-019-0219-6 Mishmar, 2003, Natural selection shaped regional mtDNA variation in humans, Proc. Natl. Acad. Sci. U. S. A., 100, 171, 10.1073/pnas.0136972100 Aikhionbare, 2008, mtDNA sequence variants in subtypes of epithelial ovarian cancer stages in relation to ethnic and age difference, Diagn. Pathol., 3, 32, 10.1186/1746-1596-3-32 Piyarathna, 2019, ERR1 and PGC1alpha associated mitochondrial alterations correlate with pan-cancer disparity in African Americans, J. Clin. Invest., 129, 2351, 10.1172/JCI127579 Meng, 2019, Circulating mitochondrial DNA is linked to progression and prognosis of epithelial ovarian cancer, Transl. Oncol., 12, 1213, 10.1016/j.tranon.2019.05.015 Chornokur, 2015, Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk, PLoS One, 10, 10.1371/journal.pone.0128106 Palmieri, 2013, The mitochondrial transporter family SLC25: identification, properties and physiopathology, Mol. Asp. Med., 34, 465, 10.1016/j.mam.2012.05.005 Huerta-Yépez, 2016, Role of diets rich in omega-3 and omega-6 in the development of cancer, Bol. Med. Hosp. Infant. Mex., 73, 446 Hetland, 2012, MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival, Gynecol. Oncol., 126, 460, 10.1016/j.ygyno.2012.05.029 Schildkraut, 2007, Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer, Cancer Epidemiol. Biomark. Prevent., 16, 473, 10.1158/1055-9965.EPI-06-0868 Chamberlain, 1994, The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function, Nucleic Acids Res., 22, 3181, 10.1093/nar/22.15.3181